Optoacoustic sensors for early disease detection and monitoring

Project Information

RSENSE4Health

Grant agreement ID: 101034883

DOI

10.3030/101034883

Project closed

EC signature date 16 March 2021

Start date 1 September 2021

End date 31 May 2023

Funded under

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Total cost

No data

EU contribution

€ 100 000,00

Coordinated by

TECHNISCHE UNIVERSITAET MUENCHEN
Germany

Periodic Reporting for period 1 - RSENSE4Health (Optoacoustic sensors for early disease detection and monitoring)

Reporting period: 2021-09-01 to 2023-05-31

Summary of the context and overall objectives of the project

Diabetes and cardiovascular disease (CVD) are responsible for the majority of the morbidity and mortality in the EU. However, to date there is no technology available that offers a non-invasive and portable way for disseminated measurements of disease effects on the systemic level or for monitoring disease progression from early development stages. RSENSE4Health aims to accelerate the exploitation of a powerful, portable optoacoustic sensor, developed under the RSENSE project, an EU project funded under the FET programme. For the first time, this sensor can non-invasively detect the systemic effects of diabetes and CVD developing in home environments – a performance not available to any other sensors. With more than one billion potential users, this technology has an enormous market and global impact potential. To bring this innovation to the market, RSENSE4Health will sharpen product specifications with stakeholder interviews, solidify patent strategy, and identify an optimal regulatory and business roadmap in order to accelerate company spin-off and product launch.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

A market analysis was performed to define product specifications for market deployment; develop an implementation roadmap; and identify regulatory barriers and requirements. The work carried out on RSENSE4Health was based on the optoacoustic medical sensor developed through RSENSE Project (GA #862811). We have successfully identified pathways towards a health insurance reimbursement and confirmed interest by key opinion leaders and other relevant stakeholders in our product. A market entry strategy was developed.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

RSENSE4Health promises to drive healthcare transition by providing so far inaccessible diagnostic biomarkers, e.g. microvessel parameters linked to diabetes and CVD. For the first time, this performance can enable remote diagnostics and therapy monitoring of these diseases, beyond the wellness use of current wearables.
When the sensor is ready and launched, we foresee the following socio-economic impacts:
- Our innovation will contribute to strengthen the position of the EU as global market leader in healthcare provision and MedTech development maintaining independence from other technologies and countries
- Ease the burden of disease of diabetes and CVD
- Longitudinal Precision Medicine and personalised therapy
- Reduce healthcare costs
- Improve healthcare access

RSENSE4Health logo